In a single-center study, 32 subjects with knee osteoarthritis were randomized to receive either intravenous VOLT01 or zoledronic acid.
The study found that that VOLT01 significantly reduced pain as compared to ZA when measured by the change in mean Visual Analogue Scale and significantly decreased the incidence of post-dose syndrome as compared to ZA. Only 12.5 percent of patients receiving VOLT01 had PDS as compared to 56.3 percent of those who received ZA.
A current phase III multi-center clinical trial with in Australia will assess VOLT01 for controlling knee osteoarthritis with results expected in 2015.
More articles on orthopedics:
Dr. Patricia McDougall Schick joins Prevea Regional Orthopedic Center
AAOS census: 5 most common orthopedist specialty areas
American Society for Surgery of the Hand honors Dr. Mark Vitale
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
